{"schema_version":"secwatch.filing_event.v1","accession":"0001581280-26-000044","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2026-08-03T11:21:11+00:00","discovered_at":"2026-08-03T11:25:04.602998+00:00","generated_at":"2026-08-03T11:25:11.467732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Twist Bioscience Q3 FY2026 revenue $118.4M (+23% YoY); raises FY guidance to $456-457M","bullets":["Record revenue of $118.4M, up 23% YoY; 14th consecutive quarter of sequential growth.","Gross margin 52.8%, up 120 bps sequentially; DSPS revenue $56.6M (+39% YoY), NGS $61.8M (+12% YoY).","Net loss $35.1M ($0.56/share) vs net income $20.4M ($0.33) in prior year which included $48.8M gain from Atlas spin-out.","Adjusted EBITDA -$11.3M; company reiterates Q4 FY2026 adjusted EBITDA breakeven target.","FY2026 revenue guidance raised to $456-457M, up $12M at midpoint; cash $167M."],"urls":{"canonical":"https://secwatch.observer/filing/0001581280-26-000044","json":"https://secwatch.observer/filing/0001581280-26-000044.json","markdown":"https://secwatch.observer/filing/0001581280-26-000044.md","text":"https://secwatch.observer/filing/0001581280-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000044/0001581280-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000044/twist-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:25:11.467732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}